Heart Failure

Cardiovascular Clinical Consult

Adult Immunization

Hepatic Disease 

Behcet’s Disease

Rare Disorders

Pediatric Immunization

Implementing The Topcon Ocular Telehealth Platform

Weight Management

Screening

Monkeypox

Guidelines

Men's Health

Panic Disorder  

Anxiety

Eating Disorders

Depression

Substance-related Disorders

ADHD

Psychiatry 

Seasonal Allergies

Allergy

Nutrition 

Pregnancy and Birth

Women's Health

Atrial Fibrillation

Cholesterol Disorders

Cardiovascular Disease

Hypertension

Cardiology

Substance Use

Child/Adolescent

Pediatrics

Kidney Disease

Genetics

Medical Cannabis

Complimentary & Alternative Medicine

Skin Diseases

Dermatology

Thyroid Disorders 

Diabetes

Diabetes Type 2

Insulin

Endocrinology 

Oral Medicine 

Otorhinolaryngologic Diseases

Fibromyalgia

Pain

Irritable Bowel Syndrome 

Inflammatory Bowel Disease

Gastrointestinal Disorders

Geriatrics

Coronavirus

Hepatitis C

Cold, Cough, and Flu

Bacterial Conjunctivitis

Immunization

Influenza

HIV AIDS

Sexually Transmitted Diseases

Infection

Osteoporosis

Imaging 

Musculoskeletal Disorders  

Obesity

Rheumatoid Arthritis

Arthritis

Gout

Rheumatology

Technology

Colorectal Cancer

Kidney Cancer

Lung Cancer

Melanoma

Skin cancer

Prostate Cancer

Breast Cancer

Cervical Cancer

Cancer

Nephrology

Anemia

Dementia

Epilepsy

Cerebrovascular Diseases

Headache and Migraine

Parkinson Disease

Alzheimer disease

Stroke

Mental Health

Headache

Migraine

Nervous System Diseases

Sleep Disorders

Neurology

Asthma

Cystic Fibrosis

COPD

Pneumonia

Respiratory Diseases

Pulmonology

News

All News

Office Procedures

Practice Management

Media

Around the Practice

Between the Lines

ConsultantLive

Expert Interviews

Institutional Insights

Medical World News

Podcasts

Primary View

Provider Toolkits

Readout360

Conferences

Conference Coverage

Conference Listing

Resources

Image IQ

Interactive Posters

Polls

Publications

Quizzes

Subscribe

CE/CME

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Information

Patient Care Online

Facebook

LinkedIn

Clinical Focus

Allergy & Immunology

Endocrinology

Gastroenterology

Infectious Disease

Men’s Health

Pain Management

Psychiatry

Women’s Health

Business Focus

Billing and Collections

Career Planning

Coding and Documentation

Concierge Medicine

Cybersecurity

EHRs

Investing

Patient Relations

Personal Finance

Remote Patient Monitoring

Staffing

Telehealth

Value-based Care

Spotlight

Unmet Needs in Managing MDD

Interpreting Thyroid Function Tests

Using Thyroid Lab Tests

Testing & Screening to Optimize Men's Health

1rem

Clinical Topics

Topics

Cheryl Pirozzi, MD, MS; Charlie Strange, MD

Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema

Emma Guttman-Yassky, MD, PhD; Linda Stein Gold, MD 

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

Edwin Kim, MD, MS; Christina Ciaccio, MD, MSc; Jay A. Lieberman, MD

Community Practice Connections™: Navigating a New Era of Food Allergy Management

The needle-free nasal spray, if approved, would be the first new administration method for epinephrine in young children in 35 years. 

sNDA Goes to FDA for neffy 1 mg for Young Children with Type 1 Allergic Reactions

Your daily dose of the clinical news you may have missed.

FDA Approves Neffy as First Nasal Spray for Allergic Reactions: Daily Dose

neffy (epinephrine nasal spray) is the first alternative to epinephrine administered by autoinjector or syringe and is comparable in efficacy to the gold standard. 

FDA Approves First Intranasal Epinephrine for Emergency Treatment of Allergic Reactions 

PK data from a self-administration study are comparable to those seen following administration by a clinician and Tmax equal at 15 minutes. 

Topline PK Data Released on Self-Administered Epinephrine Sublingual Film for Severe Allergy 

Positive findings from a repeat dosing study of neffy under nasal allergen challenge conditions will support a potential PDUFA date of October 2, 2024, the company said. 

ARS Pharma Submits Response to FDA Complete Response Letter for neffy (epinephrine nasal spray) 

Tezepelumab, a thymic stromal lymphopoietin antagonist, 

by the FDA in December 2021 (Tezspire) as add-on maintenance therapy for patients with severe asthma whose symptoms remain uncontrolled on guideline-recommended therapy. Approval was based on findings from the phase 3 

In a presentation at the annual American Academy of Asthma, Allergy, & Immunology meeting, Tara Carr, MD, presented results of a 

 of NAVIGATOR data that assesed the efficacy of tezepelumab in a broad population of patients with severe, uncontrolled 

 comorbidities. Carr spoke with Patient Care Online about the analysis and implications for primary care practice.

is associate professor of medicine and otolaryngology, director, Adult Allergy Program and director, Allergy & Immunology Fellowship Program, Asthma and Airway Disease Research Center, at the University of Arizona College of Medicine in Tucson, Arizona. 

Videos

Tara Carr, MD, led a post hoc analysis of the NAVIGATOR phase 3 trial and presented data on tezepelumab efficacy in the vulnerable subgroup at the AAAAI 2022 meeting.   

Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities 

Allergy

Latest News